Prognostic interaction between thrombocytosis and JAK2 V617F mutation in the WHO subcategories of myelodysplastic/myeloproliferative disease-unclassifiable and refractory anemia with ringed sideroblasts and marked thrombocytosis. Leukemia 2008 Jun;22(6):1295-8
Date
12/07/2007Pubmed ID
18059483DOI
10.1038/sj.leu.2405054Scopus ID
2-s2.0-45149121653 (requires institutional sign-in at Scopus site) 26 CitationsAuthor List
Atallah E, Nussenzveig R, Yin CC, Bueso-Ramos C, Tam C, Manshouri T, Pierce S, Kantarjian H, Verstovsek SAuthor
Ehab L. Atallah MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAged
Aged, 80 and over
Anemia, Refractory
Anemia, Sideroblastic
Female
Humans
Janus Kinase 2
Male
Middle Aged
Myelodysplastic Syndromes
Myeloproliferative Disorders
Point Mutation
Prognosis
Survival Rate
Thrombocytosis
World Health Organization